Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 301–400 of 1,000
Calcium-based nanomaterials and their interrelation with chitosan: optimization for pCRISPR delivery
Rabiee, N., Bagherzadeh, M., Ghadiri, A. M., Kiani, M., Ahmadi, S., Jajarmi, V., Fatahi, Y., Aldhaher, A., Tahriri, M., Webster, T. J., et al. (2021) · Journal of nanostructure in chemistry · doi:10.1007/s40097-021-00446-1 · Cited by 44
Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation
Levings, R. W., Palmer, G. D., Levings, P. P., Dacanay, E. A., Evans, C. H., & Ghivizzani, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901317 · Cited by 53
“Over the last 7–8 years or so, gene therapy has experienced a marked re-birth (Naldini, 2015) as several gene-based treatments have achieved clinical efficacy and received FDA approval (Dunbar et al.”
BackgroundInfluentialIntelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy
Tang, Z., Deng, L., Zhang, J., Jiang, T., Xiang, H., Chen, Y., Liu, H., Cai, Z., Cui, W., & Xiong, Y. (2024) · Research · doi:10.34133/research.0477 · Cited by 60
Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future
van Karnebeek, C., Bowden, K., & Berry‐Kravis, E. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.07.010 · Cited by 49
Yang, Y., Du, T., Zhang, J., Kang, T., Luo, L., Tao, J., Gou, Z., Chen, S., Du, Y., He, J., et al. (2017) · Advanced Science · doi:10.1002/advs.201600491 · Cited by 43
Khalil, I. A., & Harashima, H. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.01.007 · Cited by 43
“Gene therapy is a promising approach for treating a wide range of inherited and acquired diseases that are not efficiently cured by conventional medicine (Collins and Thrasher, 2015; Mountain, 2000; Naldini, 2015).”
BackgroundXiang, J., Liu, X., Zhou, Z., Zhu, D., Zhou, Q., Piao, Y., Jiang, L., Tang, J., Liu, X., & Shen, Y. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13291 · Cited by 43
RNA-guided piggyBac transposition in human cells
Hew, B. E., Sato, R., Mauro, D., Stoytchev, I., & Owens, J. B. (2019) · Synthetic Biology · doi:10.1093/synbio/ysz018 · Cited by 46
Sun, W., Zhao, P., Zhou, Y., Xing, C., Zhao, L., Li, Z., & Yuan, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.044 · Cited by 44
Using Gene Editing Approaches to Fine-Tune the Immune System
Pavlovic, K., Tristán‐Manzano, M., Maldonado‐Pérez, N., Cortijo-Gutierréz, M., Sánchez-Hernández, S., Justicia-Lirio, P., Carmona-Luque, M. D., Herrera, C., Martín, F., & Benabdellah, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570672 · Cited by 54
Exploiting Single-Cell Tools in Gene and Cell Therapy
Bode, D., Cull, A. H., Rubio-Lara, J. A., & Kent, D. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702636 · Cited by 46
Chemically modified DNA nanostructures for drug delivery
Wang, Y., Lu, X., Wu, X., Li, Y., Tang, W., Yang, C., Liu, J., & Ding, B. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100217 · Cited by 61
Functionalized PAMAM constructed nanosystems for biomacromolecule delivery
Wong, K. H., Guo, Z., Law, M. K., & Chen, M. (2023) · Biomaterials Science · doi:10.1039/d2bm01677j · Cited by 43
Wang, L., Wu, J., Hu, Y., Hu, C., Pan, Y., Yu, Q., & Chen, H. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01026a · Cited by 43
Tomás, R. M. F., & Gibson, M. I. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00478 · Cited by 44
“4,5 Gene knock-in can mitigate some of these caveats; however, the efficiency of this procedure is 20%, compared to 68% for retroviruses, and off-target mutagenesis is still a concern.”
Cancer-targeted PEDF-DNA therapy for metastatic colorectal cancer
Bao, X., Zeng, J., Huang, H., Ma, C., Wang, L., Wang, F., Liao, X., & Song, X. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118999 · Cited by 43
El-Kharrag, R., Berckmueller, K., Madhu, R., Cui, M., Campoy, G., Mack, H. M., Wolf, C. B., Perez, A. M., Humbert, O., Kiem, H., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.026 · Cited by 46
Khademi, Z., Ramezani, M., Alibolandi, M., Zirak, M. R., Salmasi, Z., Abnous, K., & Taghdisi, S. M. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119691 · Cited by 45
Zhou, S., Fatima, S., Ma, Z., Wang, Y.-D., Lu, T., Janke, L. J., Du, Y., & Sorrentino, B. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.55 · Cited by 42
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“After a period of major setbacks during the late 1990s and early 2000s, this technique has reemerged as a major breakthrough in regenerative medicine (1, 2).”
BackgroundNanotechnology-enabled gene delivery for cancer and other genetic diseases
Jiang, T., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2200246 · Cited by 48
Li, Y., Wang, X., He, Z., Johnson, M., Sigen, A., Lara‐Sáez, I., Lyu, J., & Wang, W. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04191 · Cited by 44
Humbert, O., Gisch, D., Wohlfahrt, M. E., Adams, A. B., Greenberg, P. D., Schmitt, T. M., Trobridge, G. D., & Kiem, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.70 · Cited by 43
Wang, K., Chen, Q., Xue, W., Li, S., & Liu, Z. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00499 · Cited by 41
Multifunctional nucleic acid nanostructures for gene therapies
Liu, J., Wang, Z., Zhao, S., & Ding, B. (2018) · Nano Research · doi:10.1007/s12274-018-2093-x · Cited by 41
“Gene therapy has gained increasing attention in biomedical research in recent years [1, 2].”
BackgroundXu, C., Wu, Y., Li, Z., & Loh, X. J. (2018) · Materials Chemistry Frontiers · doi:10.1039/c8qm00570b · Cited by 44
Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service
van Campen, J. C., Sollars, E., Thomas, R. C., Bartlett, C. M., Milano, A., Parker, M. D., Dawe, J., Winship, P. R., Peck, G., Grafham, D. V., et al. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5040040 · Cited by 42
A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise
Pearse, Y., & Iacovino, M. (2020) · Medical Research Archives · doi:10.18103/mra.v8i2.2045 · Cited by 40
An overview of development in gene therapeutics in China
Wang, D., Wang, K., & Cai, Y. (2020) · Gene Therapy · doi:10.1038/s41434-020-0163-7 · Cited by 50
Radtke, S., Pande, D., Cui, M., Perez, A. M., Chan, Y. Y., Enstrom, M., Schmuck, S., Berger, A., Eunson, T., Adair, J. E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.010 · Cited by 45
Novel genetic therapeutic approaches for modulating the severity of β‑thalassemia (Review)
Amjad, F., Fatima, T., Fayyaz, T., Khan, M. J., & Qadeer, M. I. (2020) · Biomedical Reports · doi:10.3892/br.2020.1355 · Cited by 49
“HSC gene transfer may serve as a potential option once developed, but at present, the survival advantage of corrected HSCs is low (56).”
BackgroundGao, P., Chang, X., Zhang, D., Cai, Y., Chen, G., Wang, H., & Wang, T. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.004 · Cited by 43
Yuan, Z., Wang, B., Teng, Y., Ho, W., Hu, B., Boakye‐Yiadom, K. O., Xu, X., & Zhang, X. (2022) · Nanoscale · doi:10.1039/d1nr07880a · Cited by 42
Deng, Q., Li, X., Zhu, L., He, H., Chen, D., Chen, Y., & Yin, L. (2017) · Biomaterials Science · doi:10.1039/c7bm00334j · Cited by 41
Vermeer, L. S., Hamon, L., Schirer, A., Schoup, M., Cosette, J., Majdoul, S., Pastré, D., Stockholm, D., Holic, N., Hellwig, P., et al. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.10.009 · Cited by 38
“IntroductionWith the recent success in clinical trials using lentiviral vectors (LVs), gene therapy has seen a renaissance [1].”
BackgroundWu, J., Zheng, Y., Jiang, S., Qu, Y., Wei, T., Zhan, W., Wang, L., Yu, Q., & Chen, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01586 · Cited by 42
Ou, L., Sun, T., Liu, M., Zhang, Y., Zhou, Z., Zhan, X., Lu, L., Zhao, Q., Lai, R., & Shao, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s220057 · Cited by 40
Pharmaceutical drug development: high drug prices and the hidden role of public funding
Annett, S. (2020) · Biologia Futura · doi:10.1007/s42977-020-00025-5 · Cited by 51
Gene Therapy Based on Nucleic Acid Nanostructure
Wu, X., Wu, T., Liu, J., & Ding, B. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001046 · Cited by 43
Genetic in vivo engineering of human T lymphocytes in mouse models
Weidner, T., Agarwal, S., Perian, S., Fusil, F., Braun, G., Hartmann, J., Verhoeyen, E., & Buchholz, C. J. (2021) · Nature Protocols · doi:10.1038/s41596-021-00510-8 · Cited by 43
Liu, H., Liu, C., Ye, L., Ma, D., He, X., Tang, Q., Zhao, X., Zou, H., Chen, X., & Liu, P. (2020) · Advanced Materials · doi:10.1002/adma.202003523 · Cited by 45
Lee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 41
Cancer Treatment Evolution from Traditional Methods to Stem Cells and Gene Therapy
Dong, C., He, W., Li, Q., Lü, Y., Ju, D., Gu, Y., & Zhao, K. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211119110755 · Cited by 45
DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39
Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation
Zhou, X., Naik, S., Dakhova, O., Dotti, G., Heslop, H. E., & Brenner, M. K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.234 · Cited by 41
Retroviral Vectors for Cancer Gene Therapy
Schambach, A., & Morgan, M. A. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_2 · Cited by 43
“Retroviral vectors, including lentiviral vectors, are well known for their capacity to efficiently transduce a wide range of cell types and have been successfully used in the clinic (Aiuti et al. 2013; Biffi et al. 2013; Hacein-Bey-Abina et al. 2014; Naldini 2015) (Table 1).”
Spinozzi, G., Calabria, A., Brasca, S., Beretta, S., Merelli, I., Milanesi, L., & Montini, E. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1937-9 · Cited by 43
“These upgrades, combined with a high scalability, allow VISPA2 to be used in long term gene therapy applications, as needed when starting a clinical trial and in the context of the commercialization of gene therapy treatments [39].”
BackgroundTherapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers
Karim, M. E., Tha, K. K., Othman, I., Uddin, M. B., & Chowdhury, E. H. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020065 · Cited by 40
“Since the discovery of gene sequencing technology, the journey from concept to clinical trial has faced a lot of hurdles to attain clinical reliability [1].”
BackgroundZhang, H., Chen, Z., Du, M., Li, Y., & Chen, Y. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1510065 · Cited by 40
“Gene therapy shows great promise in the treatment of diseases such as inherited disorders, cardiovascular diseases, and cancers (Chen et al., 2013; Naldini, 2015; Lino et al., 2018).”
BackgroundZheng, Y., Wu, Y. C., Zhou, Y., Wu, J., Wang, X., Qu, Y., Wang, Y., Zhang, Y., & Yu, Q. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20221 · Cited by 39
Jarak, I., Pereira‐Silva, M., Paiva‐Santos, A. C., Veiga, F., Cabral, H., & Figueiras, A. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101217 · Cited by 44
A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy
Liang, X., Luo, M., Wei, X., Ma, C., Yang, Y., Shao, B., Liu, Y., Liu, T., Ren, J., Liu, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10537 · Cited by 38
Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors
Bai, R.-Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019) · Gene Therapy · doi:10.1038/s41434-019-0080-9 · Cited by 38
Targeting DNA to the endoplasmic reticulum efficiently enhances gene delivery and therapy
Qin, B., Yuan, X., Jiang, M., Yin, H., Luo, Z., Zhang, J., Zhu, C., Li, X., Shi, Y., Luo, L., et al. (2020) · Nanoscale · doi:10.1039/d0nr03156a · Cited by 38
Zheng, N., Luo, X., Zhang, Z., Wang, A., & Song, W. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c07662 · Cited by 38
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic
Zimran, E., Papa, L., & Hoffman, R. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100853 · Cited by 40
McDonald, M. F., Hossain, A., Momin, E. N., Hasan, I., Singh, S. K., Adachi, S., Gumin, J., Ledbetter, D., Yang, J., Long, L., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad199 · Cited by 41
Zhang, W., Hou, Y., Yin, S., Miao, Q., Lee, K., Zhou, X., & Wang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02580-8 · Cited by 47
“Since 2015, the world-wide gene therapy trade has flourished precipitately and also assessed that in 2025, the domestic and worldwide market of gene therapy will reach nearly 31 billion US dollars [40–42].”
BackgroundVaras‐Godoy, M., Lladser, Á., Farfán, N., Villota, C., Villegas, J., Tapia, J. C., Burzio, L. O., Burzio, V. A., & Valenzuela, P. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12615 · Cited by 37
“In clinical trials, these viral vectors have displayed low immunogenicity and insertional genotoxicity (Naldini, 2015).”
BackgroundStem cell manipulation, gene therapy and the risk of cancer stem cell emergence
Clément, F., Grockowiak, É., Zylbersztejn, F., Fossard, G., Gobert, S., & Maguer‐Satta, V. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.07.03 · Cited by 43
“Today, GT clinical trials are focusing first on cancers, then on vascular anomalies, and on monogenic diseases (55).”
BackgroundRational design and biomedical applications of DNA-functionalized upconversion nanoparticles
Liu, X., Liu, M., Chen, J., Li, Z., & Yuan, Q. (2018) · Chinese Chemical Letters · doi:10.1016/j.cclet.2018.03.004 · Cited by 39
Perfluorocarbon-based nanomedicine: emerging strategy for diagnosis and treatment of diseases
Zhang, T., Zhang, Q., Tian, J., Xing, J., Guo, W., & Liang, X. (2018) · MRS Communications · doi:10.1557/mrc.2018.49 · Cited by 39
Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer
Muhammad, T., Sakhawat, A., Khan, A. A., Ma, L., Gjerset, R. A., & Huang, Y. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1268-z · Cited by 37
Costard, L. S., Kelly, D. C., Power, R. N., Hobbs, C. J., Jaśkaniec, S., Nicolosi, V., Cavanagh, B., Curtin, C. M., & O’Brien, F. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121219 · Cited by 40
“Recent developments in the understanding of the mechanism of action of gene therapies, together with improved safety measures, has led to the expansion of their use for treatments for rare, life-threatening genetic disorders, to the potential widespread use in the treatment of more common diseases and disorders [1].”
BackgroundYang, L., Liu, Y., Wang, Y., Li, J., & Liu, N. (2021) · Clinics · doi:10.6061/clinics/2021/e2348 · Cited by 38
“(Shenyang, Liaoning, China), were housed in a temperature- and light-controlled environment under pathogen-free conditions and provided unlimited access to food and water (12/12h light/dark cycle, 60±5% humidity, and at 22±3C) (18).”
BackgroundBertolin, J., Sánchez, V., Ribera, A., Jaén, M. L., García, M., Pujol, A., Sánchez, X., MUÑOZ, S. A., Marcó, S., Pérez, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25697-y · Cited by 44
Dissociation of Survival, Proliferation, and State Control in Human Hematopoietic Stem Cells
Knapp, D. J. H. F., Hammond, C. A., Miller, P. H., Rabu, G. M., Beer, P. A., Ricicova, M., Lecault, V., Da Costa, D., VanInsberghe, M., Cheung, A. M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.003 · Cited by 37
“New applications are becoming increasingly feasible due to the widening availability of cord blood (CB) units and advances in the genetic modification of human HSCs (Naldini, 2015).”
BackgroundAlternative Splicing in Genetic Diseases: Improved Diagnosis and Novel Treatment Options
Bergsma, A. J., van der Wal, E., Broeders, M., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.008 · Cited by 52
Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice
Sii-Felice, K., Giorgi, M., Leboulch, P., & Payen, E. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.05.004 · Cited by 39
UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells
Ngom, M., Imren, S., Maetzig, T., Adair, J. E., Knapp, D. J. H. F., Chagraoui, J., Fares, I., Bordeleau, M.-È., Sauvageau, G., Leboulch, P., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.009 · Cited by 41
Uncovering the dynamics of market convergence through M&A
Aaldering, L. J., Leker, J., & Song, C. H. (2018) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2018.08.012 · Cited by 38
Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy
Aghamiri, S., Talaei, S., Roshanzamiri, S., Zandsalimi, F., Fazeli, E., Aliyu, M., Avarvand, O. K., Ebrahimi, Z., Keshavarz‐Fathi, M., & Ghanbarian, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1747429 · Cited by 41
Genetically modified cell sheets in regenerative medicine and tissue engineering
Jiang, Z., Li, N., Zhu, D., Ren, L., Shao, Q., Ke, Y., & Yang, G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120908 · Cited by 38
DNA-Loaded Cationic Liposomes Efficiently Function as a Vaccine against Malarial Proteins
Fotoran, W. L., Santangelo, R., de Miranda, B. N. M., Irvine, D. J., & Wunderlich, G. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.08.004 · Cited by 36
Xie, L., Wang, J., Song, L., Jiang, T., & Yan, F. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01398-4 · Cited by 41
“INTRODUCTION Gene delivery is a critical process that transfers foreign DNA to host cells for biomedical applications, such as genetic research or gene therapy.(1,2) In general, this process necessitates the incorporation of DNA into target cells, its release from intracellular vesicles, and transport to the nucleus,…”
BackgroundSelf-assembled nanoplatforms for chemodynamic therapy
Meng, X., Sun, Z., Chu, H., & Wang, Y. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.147702 · Cited by 36
Meng, Z., Kang, Z., Sun, C., Yang, S., Zhao, B., Feng, S., Meng, Q., & Liu, K. (2018) · Nanoscale · doi:10.1039/c7nr05843h · Cited by 36
Fernandez-Piñeiro, I., Pensado, A., Badiola, I., & Sánchez, A. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.009 · Cited by 35
Takashima, Y., Horisawa, K., Udono, M., Ohkawa, Y., & Suzuki, A. (2018) · Cancer Science · doi:10.1111/cas.13798 · Cited by 42
Jiang, Z., Cui, W., Prasad, P., Touve, M. A., Gianneschi, N. C., Mager, J., & Thayumanavan, S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01321 · Cited by 37
Wang, G., Zhu, D., Zhou, Z., Piao, Y., Tang, J., & Shen, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b22394 · Cited by 34
Li, L., Jiang, H., Chen, R., Zhou, J., Xiao, Y., Zhang, Y., & Yan, F. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0078-6 · Cited by 38
Roberts, O. L., & Paraoan, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188393 · Cited by 40
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
Zhang, C., Chen, J., Song, Y. H., Luo, J., Jin, P., Wang, X., Lei, X., Qiu, F., Yao, J., Wang, G., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c20030 · Cited by 36
CRISPR/Cas9: a historical and chemical biology perspective of targeted genome engineering
Singh, A., Chakraborty, D., & Maiti, S. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00197a · Cited by 35
Versatile Supramolecular Gene Vector Based on Host–Guest Interaction
Liu, J., Hennink, W. E., van Steenbergen, M. J., Zhuo, R., & Jiang, X. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00094 · Cited by 34
Ethical issues in genetic modification and why application matters
Munsie, M., & Gyngell, C. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.002 · Cited by 41
Song, Z., Liang, X., Wang, Y., Han, H., Yang, J., Fang, X., & Li, Q. (2019) · Biomaterials Science · doi:10.1039/c8bm01385c · Cited by 34
Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system
Blessing, D., & Déglon, N. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.004 · Cited by 42
“frequently used for rodent and primate CNS research and in gene therapy clinical trials [5,6].”
BackgroundTzoumas, N., Hallam, D., Harris, C. L., Lako, M., Kavanagh, D., & Steel, D. H. W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.10.008 · Cited by 33
Raigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 46
“69 While HSC-based gene therapy can achieve long-lasting correction within the hematopoietic system, replacing large fractions of other tissue types remains challenging due to difficulties in harvesting sufficient numbers of progenitor cells and ensuring stable engraftment.”
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 35
Benedetti, S., Uno, N., Hoshiya, H., Ragazzi, M., Ferrari, G., Kazuki, Y., Moyle, L. A., Tonlorenzi, R., Lombardo, A., Chaouch, S., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607284 · Cited by 35
“The safe use of lentiviral vectors to mediate integration and excision of the immortalising cassettes utilised in this study is supported by recent gene therapy clinical studies (Naldini, 2015).”
MethodSelf-citationImproving Lentiviral Transduction of CD34 + Hematopoietic Stem and Progenitor Cells
Hauber, I., Beschorner, N., Schrödel, S., Chemnitz, J., Kröger, N. M., Hauber, J., & Thirion, C. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.085 · Cited by 41
Magalhães, M., de Almeida, M. S., da Silva, E. J. T., Roleira, F. M. F., Varela, C. L., Jorge, J., Gonçalves, A. C., Carvalho, R. A., Veiga, F., Paiva‐Santos, A. C., et al. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.021 · Cited by 34
“As already described in the literature, gene therapy intends to use genetic material to treat or prevent monogenic diseases or complex diseases with acquired genetic defects, such as cancer (Keeler et al., 2017; Magalhães et al., 2018, 2014; Naldini, 2015).”
BackgroundGermline CRISPR/Cas9-Mediated Gene Editing Prevents Vision Loss in a Novel Mouse Model of Aniridia
Mohanna, S. Z. M., Hickmott, J. W., Lam, S. L., Chiu, N. Y., Lengyell, T. C., Tam, B. M., Moritz, O. L., & Simpson, E. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.002 · Cited by 36
Niu, G., Jin, Z., Zhang, C., He, D., Gao, X., Zou, C., Zhang, W., Ding, J., Das, B. C., Severinov, K., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102897 · Cited by 36
Chen, X., Snanoudj, S., Pollard, L., Hu, Y., Cathey, S. S., Tikkanen, R., & Gray, S. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.012 · Cited by 35
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Andreana, I., Repellin, M., Carton, F., Kryza, D., Briançon, S., Chazaud, B., Mounier, R., Arpicco, S., Malatesta, M., Stella, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020278 · Cited by 40
“They aimed at improving patient’s quality of life by i) reducing the administration frequency, thus increasing their compliance to the treatment [97,98], and ii) providing a personalised therapy for the correction of genetic mutations [99].”
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.